Type 2 & other diabetes

Glucagon-Like Peptide-1 Receptor Agonists and Risk for Gastroesophageal Reflux Disease in Patients With Type 2 Diabetes : A Population-Based Cohort Study

Ann Intern MedPublished Active-comparator new-user cohort study emulating a target trial

Authors' conclusion

The estimated effect of GLP-1 RAs compared with SGLT-2 inhibitors suggested a higher risk for GERD and its complications in patients with type 2 diabetes. Clinicians should be aware of this potential adverse effect to provide timely prevention and treatment strategies.

Study context

Population
Adults aged ≥18 years with T2D initiating GLP-1 RAs or SGLT-2 inhibitors between 1 January 2013 and 31 December 2021, follow-up until 31 March 2022; UK Clinical Practice Research Datalink
Participants
24,708 vs 89,096
Exposure
GLP-1 RAs vs SGLT-2 inhibitors
  • GLP-1 RAsn = 24,708
  • SGLT-2 inhibitorsn = 89,096reference
Outcome
Incident gastroesophageal reflux disease (GERD)
Follow-up
3 years
Methodological detailspropensity score fine stratification weighting, Limitation: residual confounding due to lack of information on dietary or lifestyle factors
  • Propensity score fine stratification weighting
  • Limitation: residual confounding due to lack of information on dietary or lifestyle factors

Main finding

As reported in the abstract

3 years; median follow-up 3.0 years
Each group vs SGLT-2 inhibitorsRelative risk (95% CI)
GLP-1 RAs
1.27(1.14–1.42)
GLP-1 RAs
RD 0.7 per 100 patients

Observational data: associations, not effects.

Secondary outcomes

OutcomeRR (95% CI)
GERD complications · 3 years; median follow-up 3.0 yearsGLP-1 RAsvs SGLT-2 inhibitors1.55 (1.12–2.29)
OutcomeRD (per 1000 patients)
GERD complications · 3 years; median follow-up 3.0 yearsGLP-1 RAs vs SGLT-2 inhibitors0.8

Original publication

Glucagon-Like Peptide-1 Receptor Agonists and Risk for Gastroesophageal Reflux Disease in Patients With Type 2 Diabetes : A Population-Based Cohort Study. Ann Intern Med. Published 15 July 2025. doi:10.7326/annals-24-03420

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.